Jörg Vollmer has significant knowledge and experience in the areas of immunology, oncology and infectious diseases, which he obtained in various R&D and executive positions over the course of his career. Jörg currently is CSO at Abalos Therapeutics GmbH and focuses on the development of a novel virus-based anti-tumor treatment. Before joining Abalos, Jörg was CSO at Rigontec GmbH where he helped advance a RIG-I RNA agonist into the clinic. Prior to this, he was CEO and Managing Director at Nexigen GmbH developing cell penetrating peptide therapeutics targeting tumor stem cell signaling pathways, and he held the position of Managing Director and Site Head at Pfizer’s Oligonucleotide Therapeutics Unit in Düsseldorf, Germany where he was responsible for therapeutic oligonucleotide research and development. Jörg started his career at Coley Pharmaceutical Group where he focused on the development of immune modulatory oligonucleotides targeting Toll-like receptors. Jörg received a PhD from the Max-Planck-Institute of Immunobiology in Freiburg, Germany.